The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy. Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

NCT00002537

Lung Cancer

COMPLETED PHASE1

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00003917

Lung Cancer

COMPLETED PHASE3

Oral Topotecan to Treat Recurrent or Persistent Solid Tumors

NCT00382733

Tumors

COMPLETED PHASE1/PHASE2

Topotecan Pharmacokinetic Characterization Study

NCT00361803

Cancer

COMPLETED PHASE1

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

NCT00682279

Advanced Solid Tumors

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer, Small Cell Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

topotecan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or biopsy.
* Women of reproductive potential must have a negative serum pregnancy test at the study screening visit.
* Patients must give written informed consent to participate in the study.
* Patients must be able to take oral medication.
* Patients should be completely recovered from recent surgery.
* Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
* Patients must be evaluated by the radiation oncologist prior to study entry.

Exclusion Criteria

* Extensive Stage SCLC.
* Women who are pregnant or lactating.
* Use of an investigational drug within 30 days prior to the first dose of study medication.
* Any medically/clinically significant active infection.
* Symptoms of the SCLC spreading to the brain.
* Patients with limited stage SCLC who have undergone complete resection with no measurable disease prior to starting chemotherapy.
* Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk.
* Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No